---
name: aria-planning
description: >
  Regulatory milestone planning with phase management, deliverables, and dependencies.
  Creates structured regulatory project plans based on pathway and estimation data.
allowed-tools: Read Grep Glob
user-invocable: false
metadata:
  version: "1.0.1"
  category: "domain"
  status: "active"
  updated: "2026-02-11"
  modularized: "false"
  tags: "planning, milestones, phases, dependencies, project-management"
  knowledge-base-date: "2026-01"

# MoAI Extension: Progressive Disclosure
progressive_disclosure:
  enabled: true
  level1_tokens: 100
  level2_tokens: 2000

# MoAI Extension: Triggers
triggers:
  keywords: ["plan", "milestone", "schedule", "roadmap", "project plan"]
  phases: ["run"]
---

# Regulatory Milestone Planning Skill

## Quick Reference

**Purpose**: Generate phase-based regulatory project plans with milestones, dependencies, and critical path analysis.

**Input**: Pathway and estimation results from `/aria:pathway` and `/aria:estimate`
**Output**: Milestone plan with phases, deliverables, dependencies, Gantt-style timeline, traffic light indicator
**Knowledge Base Date**: 2026-01

---

## Planning Framework

### Phase Structure

All regulatory plans follow a standard 4-6 phase structure:

1. **ì¤€ë¹„ ë‹¨ê³„ (Preparation)**
   - Gap analysis
   - Resource allocation
   - Strategy finalization

2. **ì‹œí—˜ ë‹¨ê³„ (Testing & Validation)**
   - Biocompatibility testing
   - Performance testing
   - Electrical safety testing
   - Software validation (if applicable)

3. **ë¬¸ì„œí™” ë‹¨ê³„ (Documentation)**
   - Technical file creation
   - Submission package assembly
   - Clinical evaluation report (if applicable)

4. **ì œì¶œ ë° ì‹¬ì‚¬ ë‹¨ê³„ (Submission & Review)**
   - Regulatory submission
   - Deficiency response
   - Approval/certification

5. **ì„ìƒì‹œí—˜ ë‹¨ê³„ (Clinical Study)** (if applicable)
   - Protocol development
   - IRB approval
   - Patient enrollment
   - Data collection and analysis

6. **ì‚¬í›„ ê´€ë¦¬ ë‹¨ê³„ (Post-Market)** (optional in initial plan)
   - Post-market surveillance setup
   - Vigilance system implementation

---

## Dependency Types

### Sequential Dependencies
- **Hard Dependency**: Task B cannot start until Task A completes
  - Example: "Documentation" depends on "Testing completion"
  - Notation: A â†’ B

### Parallel Dependencies
- **Shared Resource**: Tasks can run in parallel but share common inputs
  - Example: FDA and EU submissions both depend on "Common Testing"
  - Notation: C â‡’ A, C â‡’ B

### Milestone Dependencies
- **Checkpoint**: Multiple tasks must complete before next phase begins
  - Example: All testing must finish before documentation starts
  - Notation: [A, B, C] âŸ¹ D

---

## Plan Templates by Pathway

| Pathway | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Critical Path |
|---------|---------|---------|---------|---------|---------------|
| **510(k)** | ì¤€ë¹„ (1-2mo): Predicate search, Gap analysis | ì‹œí—˜ (2-4mo): Biocomp, Electrical, Performance | ë¬¸ì„œí™” (1-2mo): 510(k) package, SE report | ì‹¬ì‚¬ (3-6mo): Submission, Deficiency response | Phase 4 (FDA review) |
| **PMA** | IDE ì¤€ë¹„ (2-4mo): IDE app, IRB approval | ì„ìƒì‹œí—˜ (12-24mo): Patient enrollment, Data collection | PMA ë¬¸ì„œí™” (3-6mo): PMA package, QMS docs | FDA ì‹¬ì‚¬ (6-12mo): Panel meeting, Approval | Phase 2 (Clinical study) |
| **EU IIa** | ì¤€ë¹„ (1-3mo): NB selection, Tech file structure | ì‹œí—˜/CER (3-6mo): Testing, CER, PMSP | ì¸ì¦ ì‹¬ì‚¬ (2-4mo): NB audit, CE cert | - | Phase 2 (Testing/CER) |
| **MFDS G2** | ì¤€ë¹„ (1-2mo): Protocol, Doc plan | ì‹œí—˜ (2-4mo): Non-clinical tests, Validation | ë¬¸ì„œí™” (1-2mo): Approval package | ì‹¬ì‚¬ (2-4mo): MFDS submission | Phase 2 (Testing) |

---

## Multi-Region Planning

### Parallel Submission Strategy

When submitting to multiple regions simultaneously:

**Shared Phases** (run once, benefit all):
- Common Testing (biocompatibility, electrical safety, performance)
- Clinical data collection (if shared across regions)

**Region-Specific Phases** (run in parallel):
- FDA 510(k) documentation
- EU MDR technical file
- MFDS approval application

**Dependency Map**:
```
Common Testing â†’ FDA Documentation â†’ FDA Submission
              â†’ EU Documentation â†’ EU Submission
              â†’ MFDS Documentation â†’ MFDS Submission
```

**Critical Path**: Region with longest review time

---

### Sequential Submission Strategy

When staggering submissions (e.g., US first, then EU/Korea):

**Phase Order**:
1. Common Testing
2. FDA Submission â†’ FDA Approval
3. EU Submission (using FDA approval data)
4. MFDS Submission (using FDA/EU data)

**Advantage**: Later submissions can reference earlier approvals
**Disadvantage**: Longer total timeline

---

## Workflow

### Step 1: Load Input Data

Load data from prior executions:
- **Pathway Data**: `.aria/products/<product-name>/<date>/pathway.summary.md`
- **Estimation Data**: `.aria/products/<product-name>/<date>/estimate.summary.md`

If either NOT available:
- Display warning: **"âš ï¸ ê²½ë¡œ ë° ë¹„ìš© ì¶”ì • ë°ì´í„°ê°€ í•„ìš”í•©ë‹ˆë‹¤. ë¨¼ì € `/aria:pathway` ë° `/aria:estimate` ëª…ë ¹ì„ ì‹¤í–‰í•˜ì„¸ìš”."**
- Traffic Light: ğŸŸ¡ YELLOW
- STOP workflow

### Step 2: Select Plan Template

Based on loaded pathway data, select appropriate template:
- 510(k) â†’ 4-phase plan
- PMA â†’ 4-phase plan with clinical trial
- De Novo â†’ 4-phase plan with special controls
- EU MDR IIa/IIb â†’ 3-phase plan with Notified Body
- MFDS Grade 1-2 â†’ 4-phase plan
- MFDS Grade 3-4 â†’ 5-phase plan with clinical data/trial

### Step 3: Map Milestones to Timeline

Use timeline estimates from `/aria:estimate`:
- Assign duration to each phase (optimistic, expected, pessimistic)
- Calculate cumulative timeline
- Identify phase dependencies

### Step 4: Multi-Region Integration

If multiple target regions:
- Identify shared phases (common testing)
- Determine parallel vs. sequential strategy
- Map dependencies across regions
- Calculate critical path

### Step 5: Assign Traffic Light

- **ğŸŸ¢ GREEN**: Total timeline < 12 months, no clinical study, low complexity
- **ğŸŸ¡ YELLOW**: Timeline 12-24 months or clinical study required or multi-region complex dependencies

### Step 6: Generate Output

Output structure (Korean language):

```markdown
# ê·œì œ í”„ë¡œì íŠ¸ ì‹¤í–‰ ê³„íš

## ì œí’ˆ ì •ë³´
- ì œí’ˆëª…: [Product Name]
- ë¶„ì„ ì¼ì: [YYYY-MM-DD]
- ëŒ€ìƒ ì‹œì¥: [Target Markets]
- ì˜ˆìƒ ì´ ì†Œìš” ê¸°ê°„: [Timeline]

## í”„ë¡œì íŠ¸ ê°œìš”

### ëª©í‘œ
- [Target regions and pathways]

### ì „ëµ
- [Parallel / Sequential submission strategy]

### ì˜ˆìƒ ì¼ì •
- ë‚™ê´€ì : [X]ê°œì›”
- ì˜ˆìƒ: [Y]ê°œì›”
- ë¹„ê´€ì : [Z]ê°œì›”

## ë‹¨ê³„ë³„ ì‹¤í–‰ ê³„íš

### Phase 1: ì¤€ë¹„ ë‹¨ê³„ ([Duration])

**ëª©í‘œ**: [Phase objective]

**ì£¼ìš” í™œë™**:
1. [Activity 1]
2. [Activity 2]
3. [Activity 3]

**ì‚°ì¶œë¬¼ (Deliverables)**:
- [Deliverable 1]
- [Deliverable 2]
- [Deliverable 3]

**ì˜ì¡´ì„± (Dependencies)**: [Dependencies or "ì—†ìŒ"]

**ë¹„ìš© ë°°ë¶„**: â‚©[X]M ([%])

**ë‹´ë‹¹ ì¡°ì§**: [Consulting / Internal / Testing Lab]

---

### Phase 2: ì‹œí—˜ ë‹¨ê³„ ([Duration])

**ëª©í‘œ**: [Phase objective]

**ì£¼ìš” í™œë™**:
1. [Activity 1]
2. [Activity 2]

**ì‚°ì¶œë¬¼ (Deliverables)**:
- [Deliverable 1]
- [Deliverable 2]

**ì˜ì¡´ì„± (Dependencies)**: Phase 1 ì™„ë£Œ

**ë¹„ìš© ë°°ë¶„**: â‚©[X]M ([%])

**ë‹´ë‹¹ ì¡°ì§**: [Testing labs, Validation teams]

---

[Repeat for all phases]

---

## ë‹¤ì¤‘ ì‹œì¥ ë³‘ë ¬ ì œì¶œ ê³„íš

### ê³µí†µ ë‹¨ê³„ (Common Phases)
- **ì‹œí—˜ (Testing)**: [Duration]
  - ëª¨ë“  ì‹œì¥ì—ì„œ ê³µí†µ í™œìš©
  - ë¹„ìš© ì ˆê° íš¨ê³¼: [Amount or %]

### ì§€ì—­ë³„ ë³‘ë ¬ ë‹¨ê³„

#### FDA (ë¯¸êµ­)
- **ë¬¸ì„œí™”**: [Duration]
- **ì œì¶œ ë° ì‹¬ì‚¬**: [Duration]
- **Total**: [Duration]

#### EU MDR (ìœ ëŸ½)
- **ë¬¸ì„œí™”**: [Duration]
- **ì¸ì¦ ê¸°ê´€ ì‹¬ì‚¬**: [Duration]
- **Total**: [Duration]

#### MFDS (í•œêµ­)
- **ë¬¸ì„œí™”**: [Duration]
- **ì‹¬ì‚¬**: [Duration]
- **Total**: [Duration]

**ìµœì¥ ê²½ë¡œ (Critical Path)**: [Region] ([Duration])

---

## ì˜ì¡´ì„± ë§µ (Dependency Map)

```
Phase 1 (ì¤€ë¹„)
    â†“
Phase 2 (ì‹œí—˜) âŸ¹ [FDA ë¬¸ì„œí™”, EU ë¬¸ì„œí™”, MFDS ë¬¸ì„œí™”]
                       â†“              â†“               â†“
                 FDA ì‹¬ì‚¬        EU ì‹¬ì‚¬         MFDS ì‹¬ì‚¬
```

**Critical Path Highlighted**: [Longest path description]

---

## ì£¼ìš” ë§ˆì¼ìŠ¤í†¤ (Key Milestones)

| Milestone | ì˜ˆìƒ ì™„ë£Œ ì‹œì  | ì˜ì¡´ì„± | ì¤‘ìš”ë„ |
|-----------|----------------|--------|--------|
| ì‹œí—˜ ì™„ë£Œ | [Date] | Phase 1 | â˜…â˜…â˜… High |
| FDA ì œì¶œ | [Date] | ì‹œí—˜ ì™„ë£Œ | â˜…â˜…â˜… High |
| EU ì œì¶œ | [Date] | ì‹œí—˜ ì™„ë£Œ | â˜…â˜… Medium |
| MFDS ì œì¶œ | [Date] | ì‹œí—˜ ì™„ë£Œ | â˜…â˜… Medium |
| FDA ìŠ¹ì¸ | [Date] | FDA ì œì¶œ | â˜…â˜…â˜… High |

---

## ìœ„í—˜ ìš”ì†Œ ë° ì™„í™” ì „ëµ

### ì£¼ìš” ìœ„í—˜
1. **ì‹œí—˜ ì§€ì—°**: [Mitigation strategy]
2. **ì¸ì¦ ê¸°ê´€ ëŒ€ê¸° ì‹œê°„**: [Mitigation strategy]
3. **Deficiency ëŒ€ì‘**: [Mitigation strategy]

### ë¹„ìƒ ê³„íš (Contingency)
- ì˜ˆë¹„ ì‹œê°„: [Duration]
- ëŒ€ì²´ ì¸ì¦ ê¸°ê´€ í™•ë³´ (EU)
- Deficiency ëŒ€ì‘ ì „ë‹´ íŒ€ êµ¬ì„±

---

## ë‹¤ìŒ ë‹¨ê³„

1. ë‚´ë¶€ ì˜ˆì‚° ìŠ¹ì¸ ë° ìì› ë°°ë¶„
2. ì»¨ì„¤íŒ… ì—…ì²´ ë° ì‹œí—˜ ê¸°ê´€ ê³„ì•½
3. í”„ë¡œì íŠ¸ íŒ€ êµ¬ì„± ë° í‚¥ì˜¤í”„ ë¯¸íŒ…
4. ì£¼ê°„ ì§„í–‰ ìƒí™© ëª¨ë‹ˆí„°ë§ ì²´ê³„ ìˆ˜ë¦½

---

## ìœ„í—˜ë„ í‰ê°€
- **Traffic Light**: [ğŸŸ¢ GREEN / ğŸŸ¡ YELLOW]
- **í‰ê°€**: [Risk assessment]

[If YELLOW]: **âš ï¸ ì£¼ì˜**: ì´ í”„ë¡œì íŠ¸ëŠ” ë³µì¡ë„ê°€ ë†’ìœ¼ë©°, ì¼ì • ì§€ì—° ìœ„í—˜ì´ ìˆìŠµë‹ˆë‹¤. ì •ê¸°ì ì¸ ì§„í–‰ ìƒí™© ì ê²€ê³¼ ìœ ì—°í•œ ìì› ë°°ë¶„ì´ í•„ìš”í•©ë‹ˆë‹¤.

---

## ë©´ì±… ì¡°í•­
âš ï¸ **ë³¸ ê³„íšì€ ì°¸ê³  ìë£Œì´ë©°, í™•ì • ì‹¤í–‰ ê³„íšì´ ì•„ë‹™ë‹ˆë‹¤.** ì‹¤ì œ í”„ë¡œì íŠ¸ ì¼ì •ì€ ì‹œí—˜ ê²°ê³¼, ê·œì œ ê¸°ê´€ ìš”êµ¬ì‚¬í•­, ìì› ê°€ìš©ì„±, ì™¸ë¶€ í™˜ê²½ ë³€í™” ë“±ì— ë”°ë¼ ì¡°ì •ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. í”„ë¡œì íŠ¸ ì§„í–‰ ì¤‘ ì •ê¸°ì ì¸ ê³„íš ì¬ê²€í† ì™€ ì—…ë°ì´íŠ¸ê°€ í•„ìš”í•©ë‹ˆë‹¤.

---
**ìƒì„± ì¼ì‹œ**: [Timestamp]
**ARIA Plugin Version**: 2.0.0
```

### Step 7: Generate Context Simplifier Summary

Create `.summary.md` file for downstream use:

```markdown
# Planning Summary

**Product**: [Product Name]
**Date**: [YYYY-MM-DD]

## Timeline
- **Total Duration**: [X]ê°œì›” (expected)
- **Critical Path**: [Region / Phase]

## Phases
1. ì¤€ë¹„: [Duration]
2. ì‹œí—˜: [Duration]
3. ë¬¸ì„œí™”: [Duration]
4. ì‹¬ì‚¬: [Duration]

## Key Milestones
- [Milestone 1]: [Date]
- [Milestone 2]: [Date]

## Traffic Light
- **Overall Risk**: [GREEN/YELLOW]

---
This summary completes the Phase 3 pipeline (pathway â†’ estimate â†’ plan).
```

---

## Data Source Strategy

1. **Built-in Knowledge** (Primary): Phase templates and dependency frameworks
2. **Loaded Pathway Data** (Input): `.summary.md` from `/aria:pathway`
3. **Loaded Estimation Data** (Input): `.summary.md` from `/aria:estimate`

---

## Output Template (Korean)

See Step 6 for complete output structure. All user-facing text MUST be in Korean except technical abbreviations (FDA, PMA, etc.).

---

## Traffic Light Definitions

- **ğŸŸ¢ GREEN**: Total timeline < 12 months, no clinical study, single or dual-market, low complexity
- **ğŸŸ¡ YELLOW**: Timeline 12-24 months, clinical study required, or multi-region with complex dependencies
- **ğŸ”´ RED**: Not used (all plans are feasible with appropriate resources)

---

## VALID Framework Compliance

- **Verified**: Plan templates based on regulatory consulting best practices (2026-01)
- **Accurate**: Timelines match estimation data from `/aria:estimate`
- **Linked**: References to pathway and estimation outputs
- **Inspectable**: Dependency map and phase structure transparent
- **Deliverable**: Output stored in `.aria/products/<product-name>/<date>/plan.md`

---

## Version History

**v1.0.0** (2026-02-11):
- Initial implementation for Phase 3
- Phase-based plan structure (4-6 phases)
- Dependency mapping (sequential, parallel, milestone)
- Multi-region parallel/sequential strategies
- Critical path identification
- Context Simplifier integration
- Korean language output
- Traffic light system
- VALID framework compliance

---

**Knowledge Base Cutoff**: 2026-01
**Next Update**: Quarterly updates based on regulatory project management trends
